In the news
Intellegens secures first commercial contract for Alchemiteā„¢ technology

Intellegens has entered into a commercial collaboration with e-Therapeutics; the Oxford-based pioneer of Network-Driven Drug Discovery (NDD).

read more More arrow

Intellegens secures investment.

Intellegens has received funding from Cambridge Enterprise and local angel investor to further develop its algorithms and platform.

read more More arrow

A.I is changing innovation.

General intelligence is now what matters as technical specialists find themselves replaced

Read full artcle at the growth idea.More arrow

Intellegens awarded InnovateUK grant to develop platform.

Intellegens, a provider of specialist Artificial Intelligence (AI) algorithms to the drug discovery and material design sectors, has been awarded an InnovateUK grant to develop an experimental platform to enable integration of its unique algorithms with specialist software and modelling pipelines.

read more More arrow

Gaps in A.I.

A new method in artificial intelligence is taking on the challenge of making predictions from fragmentary data

Read full artcle at the growth article.More arrow

Please get in touch to see how we can help

See how our unique AI can solve real world problems